105 related articles for article (PubMed ID: 25541465)
1. Effect of styrene maleic acid WIN55,212-2 micelles on neuropathic pain in a rat model.
Linsell O; Brownjohn PW; Nehoff H; Greish K; Ashton JC
J Drug Target; 2015 May; 23(4):353-9. PubMed ID: 25541465
[TBL] [Abstract][Full Text] [Related]
2. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain.
Costa B; Colleoni M; Conti S; Trovato AE; Bianchi M; Sotgiu ML; Giagnoni G
Br J Pharmacol; 2004 Jan; 141(1):4-8. PubMed ID: 14662732
[TBL] [Abstract][Full Text] [Related]
3. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Guindon J; Desroches J; Dani M; Beaulieu P
Eur J Pharmacol; 2007 Jul; 568(1-3):173-6. PubMed ID: 17555742
[TBL] [Abstract][Full Text] [Related]
4. The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of Cancer.
Xian S; Parayath NN; Nehoff H; Giles NM; Greish K
Anticancer Res; 2015 Sep; 35(9):4707-12. PubMed ID: 26254360
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
6. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
Pascual D; Goicoechea C; Suardíaz M; Martín MI
Pain; 2005 Nov; 118(1-2):23-34. PubMed ID: 16213089
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
8. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Liang YC; Huang CC; Hsu KS
Neuropharmacology; 2007 Jul; 53(1):169-77. PubMed ID: 17572451
[TBL] [Abstract][Full Text] [Related]
9. Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.
Zhu CZ; Mikusa JP; Fan Y; Hollingsworth PR; Pai M; Chandran P; Daza AV; Yao BB; Dart MJ; Meyer MD; Decker MW; Hsieh GC; Honore P
Br J Pharmacol; 2009 Jun; 157(4):645-55. PubMed ID: 19371344
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer.
Greish K; Mathur A; Al Zahrani R; Elkaissi S; Al Jishi M; Nazzal O; Taha S; Pittalà V; Taurin S
J Control Release; 2018 Dec; 291():184-195. PubMed ID: 30367922
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.
Gunduz O; Oltulu C; Guven R; Buldum D; Ulugol A
Neurol Sci; 2011 Dec; 32(6):1135-42. PubMed ID: 21909745
[TBL] [Abstract][Full Text] [Related]
12. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain.
Walczak JS; Pichette V; Leblond F; Desbiens K; Beaulieu P
Neuroscience; 2005; 132(4):1093-102. PubMed ID: 15857713
[TBL] [Abstract][Full Text] [Related]
13. Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model.
Shahid M; Subhan F; Ahmad N; Ali G; Akbar S; Fawad K; Sewell RD
Eur J Pain; 2017 Apr; 21(4):668-680. PubMed ID: 27862616
[TBL] [Abstract][Full Text] [Related]
14. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
Fox A; Kesingland A; Gentry C; McNair K; Patel S; Urban L; James I
Pain; 2001 May; 92(1-2):91-100. PubMed ID: 11323130
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats.
Lim G; Sung B; Ji RR; Mao J
Pain; 2003 Sep; 105(1-2):275-83. PubMed ID: 14499445
[TBL] [Abstract][Full Text] [Related]
16. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat.
Vera G; Chiarlone A; Cabezos PA; Pascual D; Martín MI; Abalo R
Life Sci; 2007 Jul; 81(6):468-79. PubMed ID: 17673260
[TBL] [Abstract][Full Text] [Related]
17. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.
Potenzieri C; Harding-Rose C; Simone DA
Brain Res; 2008 Jun; 1215():69-75. PubMed ID: 18486111
[TBL] [Abstract][Full Text] [Related]
18. Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat.
Vera G; López-Gómez L; Girón R; Martín-Fontelles MI; Nurgali K; Abalo R; Uranga JA
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833878
[TBL] [Abstract][Full Text] [Related]
19. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2.
Pandolfo P; Pamplona FA; Prediger RD; Takahashi RN
Eur J Pharmacol; 2007 Jun; 563(1-3):141-8. PubMed ID: 17374533
[TBL] [Abstract][Full Text] [Related]
20. Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy.
Bujalska M
Pharmacology; 2008; 82(3):193-200. PubMed ID: 18810243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
